Table 3.

Characteristics of BC patients (n. 31) included in the study

Characteristics		Groups	N (total number 31)	%
Clinical status	Age	< 50	18	58
		≥ 50	13	42
	Clinical T	T 1-2	25	81
		T 3-4	6	19
	Clinical N	N 0	6	19
		N +	25	81
Histology (trepan biopsy)	Grad	G 1-2	22	71
		G 3-4	9	29
	Ki67	< 20	8	26
		≥ 20	23	74
	ER	Pos	29	94
		Neg	2	6
	PR	Pos	26	84
		Neg	5	16
	HER2	Pos	3	10
		Neg	28	90
Neo-adjuvant therapy*	6-12 PTX		18	58
	6 PTX - AC		4	13
	12 PTX - AC		9	29
PTX effect evaluation (US)	Residual tumor size after 2 cycles of PTX (% from initial volume)	< 50	14	45
		≥ 50	17	55
Completed scheme therapy effect evaluation (histology)	Miller and Payne system	Grade 1-2	8	26
		Grade 3-4	20	65
		Grade 5	3	10
	Residual cancer border class	I	1	3
		II	16	52
		III	11	35
		pCR	3	10

^*The schemes of neoadjuvant chemotherapy are shown by number of PTX cycles applied as monotherapy followed by combination of doxorubicin and cyclophosphamide (AC). PTX: Paclitaxel.